% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vanLeeuwen:277081,
      author       = {M. van Leeuwen and J. M. Kieffer and T. E. Young and M. A.
                      Annunziata and V. Arndt$^*$ and J. I. Arraras and D. Autran
                      and H. B. Hani and M. Chakrabarti and O. Chinot and J. Cho
                      and R. A. da Costa Vieira and A.-S. Darlington and P. R.
                      Debruyne and L. Dirven and D. Doege$^*$ and Y. Eller and M.
                      Eichler and N. Fridriksdottir and I. Gioulbasanis and E.
                      Hammerlid and M. van Hemelrijck and S. Hermann$^*$ and O.
                      Husson and M. Jefford and C. Johansen and T. K. Kjaer and M.
                      Kontogianni and P. Lagergren and E. Lidington and K. Lisy
                      and O. Morag and A. Nordin and A. S. H. Al Omari and A. Pace
                      and S. De Padova and D. Petranovia and M. Pinto and J.
                      Ramage and E. Rammant and J. Reijneveld and S. Serpentini
                      and S. Sodergren and V. Vassiliou and I. V. Leeuw and I.
                      Vistad and T. Young and N. K. Aaronson and L. V. van de
                      Poll-Franse},
      collaboration = {E. QLG},
      title        = {{P}hase {III} study of the {E}uropean {O}rganisation for
                      {R}esearch and {T}reatment of {C}ancer {Q}uality of {L}ife
                      cancer survivorship core questionnaire.},
      journal      = {Journal of cancer survivorship},
      volume       = {17},
      number       = {4},
      issn         = {1932-2259},
      address      = {New York, NY [u.a.]},
      publisher    = {Springer},
      reportid     = {DKFZ-2023-01265},
      pages        = {1111-1130},
      year         = {2023},
      abstract     = {The purpose of this study is to develop a European
                      Organisation for Research and Treatment of Cancer Quality of
                      Life Group (EORTC QLG) questionnaire that captures the full
                      range of physical, mental, and social health-related quality
                      of life (HRQOL) issues relevant to disease-free cancer
                      survivors. In this phase III study, we pretested the
                      provisional core questionnaire (QLQ-SURV111) and aimed to
                      identify essential and optional scales.We pretested the
                      QLQ-SURV111 in 492 cancer survivors from 17 countries with
                      one of 11 cancer diagnoses. We applied the EORTC QLG
                      decision rules and employed factor analysis and item
                      response theory (IRT) analysis to assess and, where
                      necessary, modify the hypothesized questionnaire scales. We
                      calculated correlations between the survivorship scales and
                      the QLQ-C30 summary score and carried out a Delphi survey
                      among healthcare professionals, patient representatives, and
                      cancer researchers to distinguish between essential and
                      optional scales.Fifty-four percent of the sample was male,
                      mean age was 60 years, and, on average, time since
                      completion of treatment was 3.8 years. Eleven items were
                      excluded, resulting in the QLQ-SURV100, with 12 functional
                      and 9 symptom scales, a symptom checklist, 4 single items,
                      and 10 conditional items. The essential survivorship scales
                      consist of 73 items.The QLQ-SURV100 has been developed to
                      assess comprehensively the HRQOL of disease-free cancer
                      survivors. It includes essential and optional scales and
                      will be validated further in an international phase IV
                      study.The availability of this questionnaire will facilitate
                      a standardized and robust assessment of the HRQOL of
                      disease-free cancer survivors.},
      keywords     = {Humans / Male / Middle Aged / Quality of Life / Cancer
                      Survivors / Neoplasms: therapy / Neoplasms: diagnosis /
                      Survivorship / Surveys and Questionnaires / Cancer survivor
                      (Other) / Disease-free (Other) / Health-related quality of
                      life (Other) / Oncology (Other) / Patient reported outcomes
                      (Other) / Survivorship questionnaire (Other)},
      cin          = {C071 / C070 / M110},
      ddc          = {610},
      cid          = {I:(DE-He78)C071-20160331 / I:(DE-He78)C070-20160331 /
                      I:(DE-He78)M110-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35088246},
      doi          = {10.1007/s11764-021-01160-1},
      url          = {https://inrepo02.dkfz.de/record/277081},
}